Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
Search
 
My Lists

Affymetrix  (Stock symbol: AFFX ) Acquired by Thermo Fisher Scientific (2016 $ 1,300,000,000 )

3420 Central Expresway
Santa Clara, CA 95051
USA
(408)-731-5000
Website Company Summary Management Team
Board

Outside board: (May no longer be on the board) Robert H Trice (Lockheed Martin SVP Business Development) Gary S Guthart (Intuitive Surgical President/COO) Jami Nachtsheim (Intel Former Director of Marketing) Robert P Wayman (HP Former CFO) Frank Witney (Affymetrix President/CEO) Daniel N Swisher (Viracta Therapeutics CEO) Riccardo Pigliucci (Aldwych Associates Managing Partner) Nelson C Chan (Magellan Former CEO) John A Young (HP)
Former outside board: Susan E Siegel (Affymetrix Former President) Susan Desmond-Hellmann (Genentech) Stephen A Fodor (Affymetrix Executive Chairman) Paul Berg (Stanford-Beckman Center) John D Diekman (Bay City Capital);  Doug Hurt (Glaxo Wellcome CFO);  Vernon R Loucks (Baxter International CEO) Barry Ross (Glaxo Wellcome R&D)
Company

Business description: Affymetrix is dedicated to developing state-of-the-art technology for acquiring, analyzing, and managing complex genetic information for use in biomedical research. Affymetrix is a market leader in creating breakthrough tools that are driving the genomic revolution. By applying the principles of semiconductor technology to the life sciences, Affymetrix develops and commercializes systems that help scientists alleviate human suffering and improve the quality of life. Leveraging technologies adapted from the semiconductor industry, the manufacture of GeneChip arrays uses photolithography and solid-phase chemistry to produce arrays containing hundreds of thousands of oligonucleotide probes packed at extremely high densities. The probes are designed to maximize sensitivity, specificity, and reproducibility, allowing consistent discrimination between specific and background signals, and between closely related target sequences.
Customers include: MerckParAllele BioscienceRoche;  American Home Products;  Baylor College of Medicine ;  Children's Hospital of Philadelphia ;  Empire Genomics ;  Genetic Association Information Network ;  Korea NIH ;  Schering-Plough
Partners include: AviaraDxDuke University HPIconix Biosciences MerckPathWork Informatics PioneerRoche;  Ardais;  BioMerieux;  Boston University Medical Center;  Broad Institute ;  CapitalBio ;  Children's Research Institute ;  Epigenomics ;  Genetics Institute;  Glaxo;  Imperial College London ;  Millenium;  NIAID;  Schering-Plough;  ScreenCell ;  TIGR;  Vita Genomics ;  Whitehead Institute
Capital

Ownership: Acquired by Thermo Fisher Scientific (2016 $ 1,300,000,000 )
Stock Symbol: AFFX
VCs include: College Retirement Equities Fund;  R.A. Investments;  GlaxoWellcom

Last Tweets


 

Last Mentions


Overview
Record updated: Mar 2016
Sector: Medical
Year Founded: 1991
Headcount: 701-800 as of Feb 2019
Ownership: Acquired by Thermo Fisher Scientific (2016 $ 1,300,000,000 )
Stock Symbol: AFFX